

**Supplementary Figure S1.** Proportion of patients in the (A) tenofovir amibufenamide (TMF) group and (B) the blank control group with high-normal ALT (0.5~1× ULN) and low-normal ALT (≤0.5 ULN) at baseline and at week 48 (FAS).